Susan G. Komen® supporters have exceeded the goal of a recent crowdfunding match challenge by raising $4.8 million for metastatic breast cancer research, alongside significant progress and continued funding of four Komen-supported researchers studying metastatic disease – the breast cancer responsible for most of the nation's 41,000 annual breast cancer deaths.
“The $4.8 million raised is going to make a significant impact in our mission to reduce breast cancer deaths through research and programs, while also providing real-time support for those facing metastatic breast cancer today,” said Susan G. Komen President and CEO, Paula Schneider. “We are so grateful to the many individuals who contributed to this vital research.”
In addition to the potential advances in research that can be achieved with these funds, there remains a need for new therapies that improve outcomes and quality-of-life for people living with metastatic disease. Breast cancer treatment options have greatly improved because of patient participation in clinical trials. Clinical trials help open the doors to new therapies and procedures that may be even more effective than current treatments.
Susan G. Komen offers a Breast Cancer Clinical Trial Information Helpline –1-877 GO KOMEN (1-877-465-6636) – to support those in need of clinical trial information and resources. Additionally, Komen in collaboration with BreastCancerTrials.org offers a custom matching service to help patients find clinical trials that fit their needs. Those seeking more information on the matching program or who wish to join the fight against breast cancer can visit komen.org.
Many of these initiatives are supported by a generous contribution from Odonate Therapeutics, a company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate and an affiliated partner made a total contribution of $2.0 million, including a match of $1.5 million of other donations received.